Levetiracetam monotherapy for elderly patients with epilepsy

63Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

We retrospectively identified 14 elderly patients with a history of partial seizures who received levetiracetam (LEV) monotherapy. Patients began LEV either as first line therapy (n = 5) or were converted to LEV monotherapy (n = 9) after failing prior antiepileptic medications (AEDs). Thirteen patients continued on LEV monotherapy for at least 6 months. One patient was lost to follow-up. Eight patients (61.5%) became seizure free. Four patients who began LEV as a first line therapy became seizure free, whereas the remaining four patients who converted to LEV after they failed their previous AEDs became seizure free. Four patients (30.7%) had more than a 50% seizure reduction of seizures. Only one patient had no significant change in seizure frequency after started on LEV. The total dosages used to control seizures were 500-3000 mg/day, (mean 1839.2 mg/day). LEV monotherapy can be effective and well tolerated in this group of patients. A prospective, larger, double blind monotherapy study is needed to confirm this finding. © 2003 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.

Author supplied keywords

Cite

CITATION STYLE

APA

Alsaadi, T. M., Koopmans, S., Apperson, M., & Farias, S. (2004). Levetiracetam monotherapy for elderly patients with epilepsy. Seizure, 13(1), 58–60. https://doi.org/10.1016/S1059-1311(03)00070-0

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free